BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast

Published

NEW HAVEN, Conn.--(BUSINESS WIRE)-- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 14, 2019 at 8:30 AM Eastern Time to discuss its third quarter 2019 operating and financial results.

Conference Call & Webcast Details

Date/Time: Thursday, November 14, 2019, 8:30 AM Eastern Time Domestic: 877-407-2985 International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay Domestic: 877-660-6853 International: 201-612-7415 Conference ID: 13696573

*Replay available through November 28, 2019

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191107005354/en/

BioXcel Therapeutics, Inc. www.bioxceltherapeutics.com

Investor Relations: John Graziano jgraziano@soleburytrout.com 1.646.378.2942

Media: Julia Deutsch jdeutsch@soleburytrout.com 1.646.378.2967

Source: BioXcel Therapeutics, Inc.

In This Story

BTAI